FDA Indications & Patient Selection

Approximately 70% of patients with NYHA Class III CHF have normal QRS duration.

The Optimizer® Smart system received FDA approval on March 21, 2019. The device has been approved in countries covered by the CE mark since October 3, 2016

.

The Optimizer® Smart system is indicated to:

Improve 6-minute hall walk distance, and
Improve quality of life, and
Improve functional status

. . . for NYHA Class III heart failure patients

who have a left ventricular ejection fraction ranging from 25% to 45%
who remain symptomatic despite guideline directed medical therapy
who are in normal sinus rhythm
and who are not receiving Cardiac Resynchronization Therapy (CRT)

Select & Download Current Patient Education Materials

The Optimizer® Smart system is a unique cardiac device therapy, that was granted Breakthrough Device designation by the U.S. Food and Drug Administration, and then went on to receive a unanimous recommendation for approval based on risk-benefit ratio from the FDA’s advisory panel.